Oxygenta Pharmaceutical Ltd manufactures Bulk Drugs and API including Pharmaceutical preparation, and Organic Fine Chemicals.Products: Losartan potassium intermediate, Gabapentin intermediate, Antihypertensive drugs, Anti cancer drugs, Antiulcer drugs, Antiretroviral drugs, Antihypertensive drugs, Antiviral drugs.
Disclosure under Regulation 44(3) of SEBI (LODR), Regulations, 2015.
Outcome of 33rd Annual General Meeting held on 21.08.2026.
Oxygenta Pharmaceutical Limited, a subsidiary of VIRUPAKSHA ORGANICS LIMITED, has announced the publication of the notice for its 33rd Annual General Meeting (AGM) for the financial year 2025-26. This important notice for shareholders was published in both Financial Express (English) and Ninadam (Telugu) newspapers. Investors can also access these publications...
Intimation of Book Closure and Cut-off Date for the AGM
Submission of 33rd Annual Report for the Financial Year 2025-26 under Regulation 34 of SEBI (LODR), Regulations, 2015
